CN110536702A - 使用hsp90抑制剂治疗癌症的方法 - Google Patents

使用hsp90抑制剂治疗癌症的方法 Download PDF

Info

Publication number
CN110536702A
CN110536702A CN201880023110.6A CN201880023110A CN110536702A CN 110536702 A CN110536702 A CN 110536702A CN 201880023110 A CN201880023110 A CN 201880023110A CN 110536702 A CN110536702 A CN 110536702A
Authority
CN
China
Prior art keywords
cancer
inhibitor
bcl
hsp90
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880023110.6A
Other languages
English (en)
Chinese (zh)
Inventor
N.比哈里
M.赫尔南德斯
S.兰德雷特
T.徐
J.M.罗思伯格
H.利钦斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artificial Intelligence Treatment Co
Original Assignee
Artificial Intelligence Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artificial Intelligence Treatment Co filed Critical Artificial Intelligence Treatment Co
Publication of CN110536702A publication Critical patent/CN110536702A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880023110.6A 2017-02-03 2018-02-01 使用hsp90抑制剂治疗癌症的方法 Pending CN110536702A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762454113P 2017-02-03 2017-02-03
US62/454113 2017-02-03
US201762563991P 2017-09-27 2017-09-27
US62/563991 2017-09-27
US201762587886P 2017-11-17 2017-11-17
US62/587886 2017-11-17
PCT/US2018/016361 WO2018144680A1 (en) 2017-02-03 2018-02-01 Methods for treating cancer using hsp90 inhibitors

Publications (1)

Publication Number Publication Date
CN110536702A true CN110536702A (zh) 2019-12-03

Family

ID=63038389

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880023110.6A Pending CN110536702A (zh) 2017-02-03 2018-02-01 使用hsp90抑制剂治疗癌症的方法

Country Status (13)

Country Link
US (2) US10799508B2 (enExample)
EP (1) EP3576794A1 (enExample)
JP (1) JP2020505433A (enExample)
KR (1) KR20190110128A (enExample)
CN (1) CN110536702A (enExample)
AU (1) AU2018215336A1 (enExample)
BR (1) BR112019016024A2 (enExample)
CA (1) CA3052594A1 (enExample)
IL (1) IL268430A (enExample)
MX (1) MX2019009227A (enExample)
RU (1) RU2019127350A (enExample)
TW (1) TW201840337A (enExample)
WO (1) WO2018144680A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115957328A (zh) * 2022-07-13 2023-04-14 杭州百可生物科技有限公司 一种用于治疗白血病的药物组合物以及白血病的治疗方法
CN116615195A (zh) * 2020-09-17 2023-08-18 阿尔伯爱因斯坦医学院 使用bax激活剂的组合治疗

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201840337A (zh) 2017-02-03 2018-11-16 美商藍治療公司 使用ｈｓｐ９０抑制劑治療癌症的方法
CA3076915A1 (en) * 2017-09-27 2019-04-04 AI Therapeutics, Inc. Therapeutic methods relating to hsp90 inhibitors
JP2022506718A (ja) * 2018-11-08 2022-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｐｒｍｔ５阻害剤及びｂｃｌ－２阻害剤の組合せ
CN113874016A (zh) 2019-01-29 2021-12-31 福宏治疗公司 化合物及其用途
KR20220025832A (ko) * 2019-06-25 2022-03-03 타베다 세라퓨틱스, 인코포레이티드 Hsp90-결합 접합체 및 이의 병용 요법
US11285159B2 (en) 2019-11-05 2022-03-29 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax
WO2021155100A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US20230100235A1 (en) * 2020-02-05 2023-03-30 Carna Biosciences, Inc. Anticancer agent composition
KR102683903B1 (ko) * 2020-09-16 2024-07-12 한국원자력의학원 아리피프라졸을 유효성분으로 함유하는 bcl2 저해제의 항암 효과 증진용 조성물
IL301322A (en) * 2020-09-17 2023-05-01 Albert Einstein College Medicine Combination therapy using bax activator agent
US20250230244A1 (en) * 2021-10-05 2025-07-17 Board Of Regents, The University Of Texas System Methods and compositions comprising b7-h3 binding polypetides
CN114588269B (zh) * 2022-04-06 2023-06-27 宁波大学附属人民医院 Bcl-2抑制剂和HDAC抑制剂的组合物及其用途
WO2024006292A2 (en) * 2022-06-27 2024-01-04 Foghorn Therapeutics Inc. Methods of treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002895A (zh) * 2010-02-12 2013-03-27 尼基制药公司 治疗血液癌症的方法
CN103998935A (zh) * 2011-04-28 2014-08-20 斯隆-凯特林癌症研究所 Hsp90组合疗法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060253A2 (en) 2009-11-13 2011-05-19 Myrexis, Inc. Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
TW201840337A (zh) 2017-02-03 2018-11-16 美商藍治療公司 使用ｈｓｐ９０抑制劑治療癌症的方法
CA3076915A1 (en) 2017-09-27 2019-04-04 AI Therapeutics, Inc. Therapeutic methods relating to hsp90 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002895A (zh) * 2010-02-12 2013-03-27 尼基制药公司 治疗血液癌症的方法
CN103998935A (zh) * 2011-04-28 2014-08-20 斯隆-凯特林癌症研究所 Hsp90组合疗法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AARTHI JAYANTHAN等: "Targeting the Bcl-2 family of proteins in Hodgkin lymphoma in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737", 《LEUKEMIA & LYMPHOMA》 *
KATHARINA BLATT等: "Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma", 《ONCOTARGET》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116615195A (zh) * 2020-09-17 2023-08-18 阿尔伯爱因斯坦医学院 使用bax激活剂的组合治疗
CN115957328A (zh) * 2022-07-13 2023-04-14 杭州百可生物科技有限公司 一种用于治疗白血病的药物组合物以及白血病的治疗方法

Also Published As

Publication number Publication date
EP3576794A1 (en) 2019-12-11
CA3052594A1 (en) 2018-08-09
MX2019009227A (es) 2020-02-12
US20180221376A1 (en) 2018-08-09
US10799508B2 (en) 2020-10-13
AU2018215336A1 (en) 2019-09-12
BR112019016024A2 (pt) 2020-03-31
WO2018144680A1 (en) 2018-08-09
TW201840337A (zh) 2018-11-16
RU2019127350A3 (enExample) 2021-05-31
KR20190110128A (ko) 2019-09-27
RU2019127350A (ru) 2021-03-03
JP2020505433A (ja) 2020-02-20
IL268430A (en) 2019-09-26
US20210030759A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
US10799508B2 (en) Methods for treating cancer using HSP90 inhibitors
US20200253979A1 (en) Therapeutic methods relating to hsp90 inhibitors
US11266654B2 (en) Apilimod compositions and methods for using same
JP2020525427A (ja) 癌を処置するための方法
CN107249638B (zh) 阿匹莫德用于治疗肾癌
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
JP6833816B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
WO2013059320A1 (en) Treatment of cancers with mutant npm1 with mek inhibitors
NZ722491B2 (en) Apilimod compositions and methods for using same
HK1242204B (en) Apilimod for use in the treatment of melanoma
HK1242204A1 (en) Apilimod for use in the treatment of melanoma
CN105228611A (zh) 用于治疗或预防头颈癌的pi3激酶抑制剂与紫杉醇的组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20220603

AD01 Patent right deemed abandoned